Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pengcheng Shi

Showing results (171-180 of 182) with videos related to

Pageof 19
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 12, 2024
Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort StudyGuopan Yu, Yu Zhang, Sijian Yu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2022
Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III TrialHaiyan Zhang, Zhiping Fan, Fen Huang, et al.
JAMA Network Open|July 7, 2021
Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and OutcomesSijian Yu, Zhiping Fan, Liping Ma, et al.
Journal of Internal Medicine|October 29, 2023
Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3-ITD: A multicenter phase 2 studySijian Yu, Yu Zhang, Guopan Yu, et al.
Leukemia|November 10, 2020
IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR T cellsZhiwu Jiang, Rui Liao, Jiang Lv, et al.
Signal Transduction and Targeted Therapy|September 13, 2023
Impact of genetic patterns on sorafenib efficacy in patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: a multi-center, cohort studyRuoyang Shao, Yu Zhang, Jinping He, et al.
Experimental Hematology & Oncology|July 7, 2026
Autologous transplant versus matched sibling donor transplant in intermediate-risk AML in CR1 with no detectable MRD: a biological assignment comparative studySijian Yu, Hui Liu, Weihua Zhao, et al.
Medical Image Analysis|June 12, 2025
Evaluation of techniques for automated classification and artery quantification of the circle of Willis on TOF-MRA images: The CROWN challengeIris N Vos, Ynte M Ruigrok, Edwin Bennink, et al.
Medical Image Analysis|May 8, 2026
Multi-structure segmentation in CBCT volumes: The ToothFairy2 challengeFederico Bolelli, Luca Lumetti, Niels van Nistelrooij, et al.
Leukemia|May 28, 2025
High-dose cytarabine with idarubicin consolidation for acute myeloid leukemia in first complete remission: a randomized controlled trialYu Zhang, Zinan Feng, Jing Du, et al.
Pageof 19

Showing results (171-180 of 182) with videos related to

Sort By:
Pageof 19
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 12, 2024
Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort StudyGuopan Yu, Yu Zhang, Sijian Yu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2022
Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III TrialHaiyan Zhang, Zhiping Fan, Fen Huang, et al.
JAMA Network Open|July 7, 2021
Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and OutcomesSijian Yu, Zhiping Fan, Liping Ma, et al.
Journal of Internal Medicine|October 29, 2023
Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3-ITD: A multicenter phase 2 studySijian Yu, Yu Zhang, Guopan Yu, et al.
Leukemia|November 10, 2020
IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR T cellsZhiwu Jiang, Rui Liao, Jiang Lv, et al.
Signal Transduction and Targeted Therapy|September 13, 2023
Impact of genetic patterns on sorafenib efficacy in patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: a multi-center, cohort studyRuoyang Shao, Yu Zhang, Jinping He, et al.
Experimental Hematology & Oncology|July 7, 2026
Autologous transplant versus matched sibling donor transplant in intermediate-risk AML in CR1 with no detectable MRD: a biological assignment comparative studySijian Yu, Hui Liu, Weihua Zhao, et al.
Medical Image Analysis|June 12, 2025
Evaluation of techniques for automated classification and artery quantification of the circle of Willis on TOF-MRA images: The CROWN challengeIris N Vos, Ynte M Ruigrok, Edwin Bennink, et al.
Medical Image Analysis|May 8, 2026
Multi-structure segmentation in CBCT volumes: The ToothFairy2 challengeFederico Bolelli, Luca Lumetti, Niels van Nistelrooij, et al.
Leukemia|May 28, 2025
High-dose cytarabine with idarubicin consolidation for acute myeloid leukemia in first complete remission: a randomized controlled trialYu Zhang, Zinan Feng, Jing Du, et al.
Pageof 19